Schwartz, J.L. et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. Contraception 74, 133-140

Harvard University, Cambridge, Massachusetts, United States
Contraception (Impact Factor: 2.34). 09/2006; 74(2):133-40. DOI: 10.1016/j.contraception.2006.02.008
Source: PubMed


Topical microbicides against the human immunodeficiency virus (HIV) 1 that are nonirritating to the female genital epithelium are urgently needed to slow the heterosexual spread of HIV infection. Products that are also effective contraceptives provide additional benefits. Cellulose sulfate (CS) is a noncytotoxic antifertility agent that exhibits in vitro antimicrobial activity against sexually transmitted pathogens, including HIV.
We performed a multicenter, Phase I, placebo-controlled, randomized study to evaluate the genital toxicity of CS. Two cohorts of healthy women used 3.5 ml of 6% CS gel or 3.5 ml of K-Y Jelly, vaginally, bid, for 14 days. The first cohort was sexually abstinent, and the second cohort was sexually active.
CS was associated with only a slightly higher odds ratio (OR) of symptoms of minor urogenital irritation compared to the inactive lubricant K-Y Jelly (OR=2.02, 95% confidence interval=0.90-4.53). In addition, there were minor shifts in some genital flora, but there was no evidence of greater inflammation as evidenced by few colposcopic findings, decreased influx of polymorphonuclear cells and minimal changes in proinflammatory cytokines. Moreover, both products appeared acceptable to most women. Product leakage was identified as more of a problem in sexually abstinent women, but less so in women using the product for sexual intercourse, as would be the case in actual practice.
CS was safe for twice-daily use for 14 days. CS is appropriate for future studies in effectiveness trials.

Download full-text


Available from: Susan A Ballagh
  • Source
    • "Contraceptive Research and Development a Division of the Department of Obstetrics and Gynecology of Eastern Virginia Medical School, 1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209) (Schwartz et al., 2006 "
    [Show abstract] [Hide abstract]
    ABSTRACT: The development of topical microbicides for intravaginal use to prevent HIV infection requires that the drugs and formulated products be nontoxic to the endogenous vaginal Lactobacillus. In 30min exposure tests we found dapivirine, tenofovir and UC781 (reverse transcriptase inhibitor anti-HIV drugs) as pure drugs or formulated as film or gel products were not deleterious to Lactobacillus species; however, PSC-RANTES (a synthetic CCR5 antagonist) killed 2 strains of Lactobacillus jensenii. To demonstrate the toxicity of formulated products a new assay was developed for use with viscous and non-viscous samples that we have termed the Lactobacillus toxicity test. We found that the vortex mixing of vaginal Lactobacillus species can lead to reductions in bacterial viability. Lactobacillus can survive briefly, about 2s, but viability declines with increased vortex mixing. The addition of heat inactivated serum or bovine serum albumin, but not glycerol, prevented the decrease in bacterial viability. Bacillus atrophaeus spores also demonstrated loss of viability upon extended mixing. We observed that many of the excipients used in film formulation and the films themselves also afford protection from the killing during vortex mixing. This method is of relevance for toxicity for cidal activities of viscous products.
    Full-text · Article · Feb 2012 · Journal of microbiological methods
  • Source
    • "In addition to the increased susceptibility to HSV, a modest but significant increase in IFN-γ, TNF-α, and IL-1β was detected in vaginal washes, which may have contributed to the epithelial barrier dysfunction. Phase I clinical studies, however, did not report an increase in cervicovaginal cytokines or chemokines upon repeated exposure to CS gel [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite significant protection in preclinical studies, cellulose sulfate (CS) failed to protect women against HIV-1/2 and was associated with a trend toward increased HIV-1 acquisition in one of the clinical trials. These results highlight the need for preclinical tests more predictive of clinical outcomes. The objective of this study was to test coded vaginal gels, including CS, in murine models of safety and efficacy to determine the models' utility for evaluating future products. Four coded formulations, including 6% CS, 2% PRO 2000 and two placebo gels, were administered intravaginally to medroxyprogesterone-treated mice and their ability to prevent genital herpes (efficacy) or to alter the susceptibility to low dose HSV challenge (safety) was determined. Nonoyxnol-9 served as a positive toxicity control. CS and PRO 2000 significantly protected mice from genital herpes following infection with a laboratory or clinical isolate of HSV-2 introduced in buffer (p<0.001). However, protection was reduced when virus was introduced in seminal plasma. Moreover, mice were significantly more susceptible to infection with low doses of HSV-2 when challenged 12 h after the 7th daily dose of CS or nonoxynol-9 (p<0.05). The increased susceptibility was associated with alterations in epithelial architecture. CS prevented genital herpes when present at the time of viral challenge, but increased the rate of infection when gel was applied daily for 7 days with a vaginal wash prior to viral inoculation. The findings presumably reflect altered epithelial architecture, which may have contributed to the trend towards increased HIV observed clinically.
    Full-text · Article · Nov 2011 · PLoS ONE
  • Source
    • "Efficacy trial of spermicidal agents [12] NIH/NICHD Single and multiple exposure tolerance study of three concentrations of C31G: once-and twice-daily exposure [13] CONRAD Lea contraceptive: colposcopy and microbiological testing [14] CONRAD Safety and acceptability of the Femcap with removal strap [15] CONRAD Phase I 14-day safety and acceptability study of ACIDFORM gel ⁎ CONRAD Phase I 14-day safety and acceptability study of 6% cellulose sulfate [16] CONRAD A multicenter, double-masked, comparative study of the safety and contraceptive efficacy of BufferGel spermicide used with diaphragm compared to Gynol II spermicide used with diaphragm [17] NIH/NICHD "
    [Show abstract] [Hide abstract]
    ABSTRACT: Colposcopy is commonly used for genital tract assessment in safety studies on female-controlled vaginal products. However, findings that are considered "lesions" are present even without product use. We sought to categorize the type and frequency of lesions found on baseline colposcopy evaluation in healthy women to describe natural lower genital tract changes due to environmental factors. We reviewed demographic information and baseline colposcopic examination findings from subjects in 13 studies of vaginal products. All studies included an aim of identifying colposcopic changes as a means of monitoring safety of a vaginal product or device. Colposcopic evaluations were performed according to the WHO/CONRAD Manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products. A total of 317 lesions were found on 569 baseline colposcopy evaluations, with 192 women (34%) having at least one lesion. The most commonly identified lesions were petechiae and erythema, accounting for 45% and 37% of lesions, respectively. Seventy-three percent of lesions were located on the cervix, whereas 15% of lesions were located on the vaginal wall or fornix. Lower genital tract colposcopic findings are common in healthy women. Such findings likely represent normal physiologic changes. Future research needs to address whether routine colposcopic examination is necessary in the evaluation of new vaginal products.
    Full-text · Article · Sep 2008 · Contraception
Show more